Provided by Tiger Trade Technology Pte. Ltd.

Day One Biopharmaceuticals Inc.

11.33
+2.3926.73%
Post-market: 11.06-0.2694-2.38%19:55 EST
Volume:8.03M
Turnover:88.03M
Market Cap:1.16B
PE:-7.68
High:11.55
Open:10.83
Low:10.45
Close:8.94
52wk High:13.53
52wk Low:5.64
Shares:102.68M
Float Shares:78.77M
Volume Ratio:4.92
T/O Rate:10.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4748
EPS(LYR):-1.0243
ROE:-30.16%
ROA:-18.57%
PB:2.58
PE(LYR):-11.06

Loading ...

Day One Biopharma Shares Rise on Ojemda Sales Outlook

Dow Jones
·
Yesterday

Day One reports preliminary FY25 Ojemda net product revenue of $155.4M

TIPRANKS
·
Yesterday

Day One Biopharmaceuticals Projects 2026 OJEMDA Revenue of $225–$250 Million

Reuters
·
Yesterday

Day One Announces Preliminary 2025 Ojemda™ Net Product Revenue and Provides 2026 Net Product Revenue Guidance

THOMSON REUTERS
·
Yesterday

Mersana Therapeutics Shareholders to Receive $25 Per Share in Acquisition by Day One Biopharmaceuticals

Reuters
·
Jan 06

Day One Biopharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference

Reuters
·
Dec 16, 2025

Buy Rating Affirmed for Day One Biopharmaceuticals Based on Promising Long-Term Data from FIREFLY-1 Trial

TIPRANKS
·
Nov 25, 2025

Day One Biopharmaceuticals Reveals Promising Phase 2 Trial Results

TIPRANKS
·
Nov 25, 2025

Day One Biopharm Price Target Maintained With a $16.00/Share by Needham

Dow Jones
·
Nov 24, 2025

Day One Biopharmaceuticals Reports Three-Year Data Showing Durable Responses for OJEMDA in Pediatric Low-Grade Glioma

Reuters
·
Nov 24, 2025

Day One Announces Three Year Follow-up Data From Ojemda™ (Tovorafenib) Phase 2 Firefly-1 Trial at the 2025 Society for Neuro-Oncology (Sno) Annual Meeting

THOMSON REUTERS
·
Nov 24, 2025

Press Release: Day One Announces Three Year Follow-Up Data From OJEMDA(TM) (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

Dow Jones
·
Nov 24, 2025

BUZZ-Nasdaq biotech index hits record high, set to gain nearly 5% this week

Reuters
·
Nov 15, 2025

Mersana Therapeutics reports third quarter 2025 financial results

Reuters
·
Nov 14, 2025

Sector Update: Health Care Stocks Edge Higher Late Afternoon

MT Newswires Live
·
Nov 14, 2025

Wedbush Adjusts Price Target on Day One Biopharmaceuticals to $29 From $25, Maintains Outperform Rating

MT Newswires Live
·
Nov 14, 2025

Day One Biopharmaceuticals Inc : Piper Sandler Cuts Target Price to $25 From $26

THOMSON REUTERS
·
Nov 14, 2025

Analysts Conflicted on These Healthcare Names: Bioxcel Therapeutics (BTAI) and Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
Nov 13, 2025

Oppenheimer says Day One paying up to $285M for Mersana ‘is interesting’

TIPRANKS
·
Nov 13, 2025

Day One Biopharmaceuticals Announces Mersana Acquisition Deal

TIPRANKS
·
Nov 13, 2025